

IN THE CLAIMS

Please amend the claims as follows.

1. (Original) Pair of oligonucleotides, for use as a set in the amplification of a target sequence of the genome of SARS Coronavirus, said pair consisting of:

a first oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 1: TACCTCTCCA GCTAGGATTT TCTACAGGTG TTAAGTTAGT
AGCTGTACCG ACTGGTTATG TTGACACTGA AAATAACACA GAATTCACCA
GAGTTAATGC AAAACCTCCA CCAGGTGACC AGTTTAAACA TCTT,

SEQ ID 14: TCAGCCCCAG ATGGTACTTC TATTACCTAG GAAGTGGCCC
AGAAGCTTCA CTT,

SEQ ID 23: TGCTCCAAGT GCCTCTGCAT TCTTTGGAAT GTCACGCATT
GGCATGGAAG TCACACCTT, or

SEQ ID 31: TGCCTATATG GAAGAGCCCT AATGTGTAAA ATTAATTTTA
GTAGTGCTAT CCCCATGTGA TTTTAATAGC TT, or the complementary sequence thereof,

a second oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 2: ATGAATTACC AAGTCAATGG TTACCCTAAT ATGTTTATCA
CCCGCGAAGA AGCTATTCGT CACGTTCGTG CGTGGATTGG CTTTGATGT,

SEQ ID 17: AGGTTTACCC AATAATACTG CGTCTTGGTT CACAGCTCTC
ACTCAGCATG GCAAGGAGGA ACTTAGATTC CCTCGAGGCC AGGGCGTTCC
AATCAACACC AATAGTGGTC CAGATGACCA AAT,

SEQ ID 26: CCAAAGTGTG ACTAAGAAAT CTGCTGCTGA GGCATCTAAA
AAGCCTCGCC AAAAACGTAC TGCCACAAAA CAGTACAACG TCACTCAAGC
ATTGGGAGA CGTGGTCCAG AACAAACCCA AGGAAATT, or

SEQ ID 34: TACGATACAT AGTCTACTCT TGTGCAGAAT GAATTCTCGT
AACTAAACAG CACAAGTAGG TTTAGTTAAC TTTAATCTCA CATAGCAATC
TTTAATCAAT GT,
or the complementary sequence thereof.

2. (Currently Amended) Pair of oligonucleotides, according to claim 1, consisting essentially of:

a first oligonucleotide comprising, at least a fragment of 10 nucleotides, of a sequence selected from the group consisting of:

SEQ ID 3: TCCACCAGGT GACCAGTTTA AACATCTT,

SEQ ID 4: TAGTAGCTGT ACCGACTGGT TATGTT,

SEQ ID 5: TACCTCTCCA GCTAGGATTT TCT,

SEQ ID 15 : TCAGCCCCAG ATGGTACTTC T,

SEQ ID 16 : TAGGAACTGG CCCAGAAGCT TCACTT,

SEQ ID 24 : TGCTCCAAGT GCCTCTGCAT TCTT,

SEQ ID 25 : TTGGCATGGA AGTCACACCT T,

SEQ ID 32 : TGCCTATATG GAAGAGCCC,

SEQ ID 33 : TCCCCATGTG ATTTTAATAG CTT,

or the complementary sequence thereof, and

a second oligonucleotide comprising, at least a fragment of 10 nucleotides, of a sequence selected from the group consisting of:

SEQ ID 6: ATGAATTACC AAGTCAATGG TTAC,

~~SEQ ID 7:~~ GAAGCTATTC GTCACGTTCG,

SEQ ID 8: TCGTGGATT GGCTTTGATG T,

SEQ ID 18 : AGGTTTACCC AATAATACTG CGT,

SEQ ID 19 : AGATTCCCTC GAGGCCAGGG CGT,

SEQ ID 20 : ATAGTGGTCC AGATGACCAA AT,

SEQ ID 27 : CCAAAGTGTG ACTAAGAAAT CTGCT,

~~SEQ~~SEQ ID 28 : CTCAAGCATT TGGGAGACGT GGT,
SEQ ID 29 : CAGAACAAAC CCAAGGAAAT T,
SEQ ID 35 : TACGATACAT AGTCTACTCT TGT,
~~SEQ~~SEQ ID 36 : TAACTAAACA GCACAAGTAG GT,
SEQ ID 37 : TAGCAATCTT TAATCAATGT,
or the complementary sequence thereof.

3. (Original) Pair of oligonucleotides, for use as a set in the amplification of a target sequence located within the replicase gene of the genome of SARS Coronavirus, said pair consisting of:

a first oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 1: TACCTCTCCA GCTAGGATTT TCTACAGGTG TTAAGTTAGT AGCTGTACCG ACTGGTTATG TTGACACTGA AAATAACACA GAATTCACCA GAGTTAATGC AAAACCTCCA CCAGGTGACC AGTTTAAACA TCTT, or the complementary sequence thereof, and

a second oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 2: ATGAATTACC AAGTCAATGG TTACCCTAAT ATGTTTATCA CCCGCGAAGA AGCTATTCGT CACGTTCGTG CGTGGATTGG CTTTGATGT, or the complementary sequence thereof.

4. (Original) Pair of oligonucleotides, according to claim 3, consisting essentially of:

a first oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 3: TCCACCAGGT GACCAGTTTA AACATCTT,
SEQ ID 4: TAGTAGCTGT ACCGACTGGT TATGTT,
SEQ ID 5: TACCTCTCCA GCTAGGATTT TCT,
or the complementary sequence thereof, and

a second oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 6: ATGAATTACC AAGTCAATGG TTAC,

SEQ ID 7: GAAGCTATTC GTCACGTTCG,

SEQ ID 8: TGCGTGGATT GGCTTTGATG T,

or the complementary sequence thereof.

5. (Original) Pair of oligonucleotides, for use as a set in the amplification of a target sequence located within the gene encoding the Nucleocapsid protein of the genome of SARS Coronavirus, said pair consisting of:

a first oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 14: TCAGCCCCAG ATGGTACTTC TATTACCTAG GAACTGGCCC
AGAAGCTTCA CTT, or the complementary sequence thereof, and

a second oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 17: AGGTTTACCC AATAATACTG CGTCTTGGTT
CACAGCTCTC ACTCAGCATG GCAAGGAGGA ACTTAGATTC CCTCGAGGCC
AGGGCGTTCC AATCAACACC AATAGTGGTC CAGATGACCA AAT, or the
complementary sequence thereof.

6. (Original) Pair of oligonucleotides, according to claim 5, consisting essentially of:

a first oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 15: TCAGCCCCAG ATGGTACTTC T,

SEQ ID 16: TAGGAACTGG CCCAGAAGCT TCACTT,

or the complementary sequence thereof, and

a second oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 18: AGGTTTACCC AATAATACTG CGT,

SEQ ID 19: AGATTCCCTC GAGGCCAGGG CGT,

SEQ ID 20: ATAGTGGTCC AGATGACCAA AT,

or the complementary sequence thereof.

7. (Original) Pair of oligonucleotides, for use as a set in the amplification of a target sequence located within the gene encoding the Nucleocapsid protein of the genome of SARS Coronavirus, said pair consisting of:

a first oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 23: TGCTCCAAGT GCCTCTGCAT TCTTTGGAAT GTCACGCATT GGCATGGAAG TCACACCTT, or the complementary sequence thereof, and

a second oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 26: CCAAAGTCTGTC ACTAAGAAAT CTGCTGCTGA GGCATCTAAA AAGCCTCGCC AAAAACGTAC TGCCACAAAA CAGTACAACG TCACTCAAGC ATTTGGGAGA CGTGGTCCAG AACAAACCCA AGGAAATT, or the complementary sequence thereof.

8. (Currently amended) Pair of oligonucleotides, according to claim 7, consisting essentially of:

a first oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 24: TGCTCCAA GTGCCTCTGC ATTCTT,

SEQ ID 25: TTGGCATGGA AGTCACACCT T, or the complementary sequence thereof, and

a second oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 27: CCAAAGTCTGTC ACTAAGAAAT CTGCT,

~~SEQ~~SEQ ID 28: CTCAAGCATT TGGGAGACGT GGT,
SEQ ID 29 : CAGAACAAAC CCAAGGAAAT T,
or the complementary sequence thereof.

9. (Original) Pair of oligonucleotides, for use as a set in the amplification of a target sequence located within the 3'-Non Coding Region (3'-NCR) of the genome of SARS Coronavirus, said pair consisting of:

a first oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of: SEQ ID 31: TGCCTATATG GAAGAGCCCT AATGTGTAAA ATTAATTTTA GTAGTGCTAT CCCCATGTGA TTTTAATAGC TT, or the complementary sequence thereof, and

a second oligonucleotide being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 34: TACGATACAT AGTCTACTCT TGTGCAGAAT GAATTCTCGT
AACTAAACAG CACAAGTAGG TTTAGTTAAC TTTAATCTCA CATAGCAATC
TTTAATCAAT GT, or the complementary sequence thereof.

10. (Original) Pair of oligonucleotides, according to claim 9, consisting essentially of:

a first oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 32: TGCCTATATG GAAGAGCCC,
SEQ ID 33: TCCCATGTG ATTTTAATAG CTT,
or the complementary sequence thereof, and

a second oligonucleotide comprising at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

SEQ ID 35: TACGATACAT AGTCTACTCT TGT,
SEQ ID 36 : TAACTAAACA GCACAAGTAG GT,

SEQ ID 37: TAGCAATCTT TAATCAATGT,
or the complementary sequence thereof.

11. (Currently Amended) Pair of oligonucleotides, according to ~~any of the claims 1-10~~claim 1, wherein the first oligonucleotide is provided with a promoter sequence recognized by a DNA dependent RNA polymerase.

12. (Original) Pair of oligonucleotides, according to claim 11, wherein the first oligonucleotide consists essentially of the sequence:

SEQ ID 9: aattctaata cgactcacta tagggAAGAT GTTTAAACTG GTCACCTGGT GGA,

SEQ ID 10: aattctaata cgactcacta tagggAACAT AACCCAGTCGG TACAGCTACT A,

SEQ ID 11: aattctaata cgactcacta tagggAGAAA ATCCTAGCTG GAGAGGTA,

SEQ ID 39: aattctaata cgactcacta tagggAGAAG TACCATCTGG GGCTGA,

SEQ ID 40: aattctaata cgactcacta tagggAAGTG AAGCTTCTGG GCCAGTTCCT A,

SEQ ID 41: aattctaata cgactcacta tagggAAGAA TGCAGAGGCA CTTGGAGCA,

SEQ ID 42: aattctaata cgactcacta tagggAAGGT GTGACTTCCA TGCCAA,

SEQ ID 43: aattctaata cgactcacta tagggGGGCT CTTCCATATA GGCA, or

SEQ ID 44: aattctaata cgactcacta tagggAAGCT ATTAAAATCA CATGGGGA.

13. (Currently Amended) Pair of oligonucleotides, according to ~~any of the claims 1-12~~claim 1, wherein each oligonucleotide being 15-30 nucleotides in length and comprising at least a fragment of 18 nucleotides, and preferably being 18-26 nucleotides in length and comprising at least a fragment of 20 nucleotides.

14. (Currently amended) Oligonucleotide, for use as a probe to detect the amplified nucleic acid sequence resulting in the amplification of a target sequence located within the genome of SARS Coronavirus, said amplification being based on pair of oligonucleotides

according to ~~any of claims 1-13~~claim 1, said probe being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 12: GTTCGTGCGT GGATTGGCTT TGATGTAGAG GGCTGTCATG
CAACTAGAGA TGCTGT,

SEQ ID 21: GGCTACTACC GAAGAGCTAC CCGACGAGTT CGTGGTGGTG
ACGGCAAAT GAAAGAGCTC AGCCCCAGAT GGTACTTCTA TTACCTAGGA
ACTGGCCCAG AAGCTTCACT TCCCTACGGC GCTAACAAAG AAGGCATCGT
ATGGGTTGCA ACTGAGGGAG CCTTGAATAC ACCCAAAGAC CACATTGGCA
CCCGCAATCC TAATAACAAT GCTGCCACCG TGCTACAACCT TCCTCAAGGA
ACAACATTGC CAAAAGGCTT CTACGCAGAG GGAAGCAGAG GCGGCAGTCA
AGCCTCTTCT CGCTCCTCAT CACGTAGTCG CGGTAATTCA AGAAATTCAA
CTCCTGGCAG CAGTAGGGGA AATTCTCCTG CTCGAATGGC TAGCGGAGGT
GGTGAAACTG CCCTCGCGCT ATTGCTGCTA GACAGATTGA ACCAGCTTGA
GAGCAAAGTT TCTGGTAAAG GCCAACAACA ACAAGGCCAA ACTGTCACTA
AGAAATCTGC TGCTGAGGCA TCTAAAAAGC CTCGCCAAAA ACGTACTGCC
ACAAAACAGT ACAACGTCAC TCAAGCATTT GGGAGACGTG GTCCAGAACA
AACCCAAGGA AATTTCGGGG ACCAAGACCT AATCAGACAA,

SEQ ID 38: GCCACCACAT TTTCATCGAG GC,

or the complementary sequence thereof, provided with a detectable label.

15. (Original) Oligonucleotide, according to claim 14, wherein the probe is constituted by a molecular beacon, preferably consisting of:

SEQ ID 13: 5'- [6-FAM]-ccatgggCTGTCATGCAACTAGAGATGCTGTcccatgg- [DabSyl]-3',

SEQ ID 45: 5'- [6-FAM]-cgcgatGTTCGTGCGTGGATTGGCTTatcgcg- [DabCyl]-3',

SEQ ID 22: 5'-[6-FAM]-ccatgggCTACTACCGAAGAGCTACCCGACGAcccatgg- [DabSyl]-3',

SEQ ID 30: 5'-[6-FAM]-ccatggACCAAGACCTAATCAGACAAccatgg- [DabSyl]-3',

SEQ ID 47: 5'-[6-FAM]-ccatgcGCCACCACATTTTCATCGAgcatgg-[DabSyl]- 3'.

16. (Currently Amended) Use of an oligonucleotides' pair, according to ~~any of the claims 1-13~~claim 1, in a nucleic acid amplification reaction or as a probe for the detection of SARS Coronavirus nucleic acid in a sample.

17. (Currently Amended) Method for the detection of SARS nucleic acid in a sample wherein the sample is subjected to a nucleic acid amplification reaction using a pair of oligonucleotides according to ~~any of the claims 1-13~~claim 1 and suitable amplification reagents and the presence of any amplified nucleic acid is detected.

18. (Currently Amended) Method according to claim 17, wherein the detection of any amplified nucleic acid is carried out by reacting the sample with an oligonucleotide ~~according to claim 14 or 15~~probe, said probe being 10-50 nucleotides in length and comprising at least a fragment of 10 nucleotides of:

SEQ ID 12: GTTCGTGCGT GGATTGGCTT TGATGTAGAG GGCTGTCATG
CAACTAGAGA TGCTGT,

SEQ ID 21: GGCTACTACC GAAGAGCTAC CCGACGAGTT CGTGGTGGTG
ACGGCAAAT GAAAGAGCTC AGCCCCAGAT GGTACTTCTA TTACCTAGGA
ACTGGCCCAG AAGCTTCACT TCCCTACGGC GCTAACAAAG AAGGCATCGT
ATGGGTTGCA ACTGAGGGAG CCTTGAATAC ACCCAAAGAC CACATTGGCA
CCCGCAATCC TAATAACAAT GCTGCCACCG TGCTACAACCT TCCTCAAGGA
ACAACATTGC CAAAAGGCTT CTACGCAGAG GGAAGCAGAG GCGGCAGTCA
AGCCTCTTCT CGCTCCTCAT CACGTAGTCG CGGTAATTCA AGAAATTCAA
CTCCTGGCAG CAGTAGGGGA AATTCTCCTG CTCGAATGGC TAGCGGAGGT
GGTGAAACTG CCCTCGCGCT ATTGCTGCTA GACAGATTGA ACCAGCTTGA
GAGCAAAGTT TCTGGTAAAG GCCAACAACA ACAAGGCCAA ACTGTCACTA
AGAAATCTGC TGCTGAGGCA TCTAAAAAGC CTCGCCAAAA ACGTACTGCC
ACAAAACAGT ACAACGTCAC TCAAGCATTT GGGAGACGTG GTCCAGAACA
AACCCAAGGA AATTTCGGGG ACCAAGACCT AATCAGACAA,

SEQ ID 38: GCCACCACAT TTTCATCGAG GC,

or the complementary sequence thereof, provided with a detectable label,
under suitable hybridization conditions and detecting the presence of the label in any hybrids
formed between the amplified sequence and the probe.

19. (Original) Method according to claim 17, wherein the amplification technique
used is a transcription based amplification technique, preferably the NASBA, and the first
oligonucleotide is provided with a promoter sequence recognized by a DNA dependent RNA
polymerase.

20. (Currently Amended) Test kit for the detection of SARS Coronavirus in a sample
comprising:

a set of oligonucleotides according any of claims 1-13 to claim 1,
an oligonucleotide comprising a nucleic acid sequence substantially complementary to at
least part of the amplified nucleic acid sequence, provided with a detectable label, ~~according to~~
~~claim 14 or 15~~ for use as a probe, said probe being 10-50 nucleotides in length and comprising at
least a fragment of 10 nucleotides of:

SEQ ID 12: GTTCGTGCGT GGATTGGCTT TGATGTAGAG GGCTGTCATG
CAACTAGAGA TGCTGT,

SEQ ID 21: GGCTACTACC GAAGAGCTAC CCGACGAGTT CGTGGTGGTG
ACGGCAAAT GAAAGAGCTC AGCCCCAGAT GGTACTTCTA TTACCTAGGA
ACTGGCCCAG AAGCTTCACT TCCCTACGGC GCTAACAAAG AAGGCATCGT
ATGGGTTGCA ACTGAGGGAG CCTTGAATAC ACCCAAAGAC CACATTGGCA
CCCGCAATCC TAATAACAAT GCTGCCACCG TGCTACAACCT TCCTCAAGGA
ACAACATTGC CAAAAGGCTT CTACGCAGAG GGAAGCAGAG GCGGCAGTCA
AGCCTCTTCT CGCTCCTCAT CACGTAGTCG CGGTAATTCA AGAAATTCAA
CTCCTGGCAG CAGTAGGGGA AATTCTCCTG CTCGAATGGC TAGCGGAGGT
GGTGAAACTG CCCTCGCGCT ATTGCTGCTA GACAGATTGA ACCAGCTTGA

ATTORNEY DOCKET NO. 9250.161
International Appn. No.: PCT/EP2004/002553
International Filing Date: 8 March 2004
Page 14

GAGCAAAGTT TCTGGTAAAG GCCAACAACA ACAAGGCCAA ACTGTCACTA
AGAAATCTGC TGCTGAGGCA TCTAAAAAGC CTCGCCAAAA ACGTACTGCC
ACAAAACAGT ACAACGTCAC TCAAGCATTT GGGAGACGTG GTCCAGAACA
AACCCAAGGA AATTTCGGGG ACCAAGACCT AATCAGACAA,
SEQ ID 38: GCCACCACAT TTTCATCGAG GC,

or the complementary sequence thereof, and
suitable amplification reagents.

21. (Original) Test kit according to claim 20, wherein suitable amplification reagents enable a transcription based amplification technique, preferably the NASBA.